使用天然蛋白质开发和评估用于持续释放glipizide的粘膜口膜
Sheeba Fr1, Ashish K Mullani2, Avinash Patel T V1
1Department of Pharmaceutics, Mallige College of Pharmacy, Bangalore, India.
Drug development and industrial pharmacy
|June 9, 2025
概括
新的粘膜口膜提供了持续的 Glipizide 输送,通过提高生物可用性和患者遵守性来改善糖尿病管理,同时减少胃肠道副作用.
科学领域:
- 制药科学 制药科学
- 药物输送系统 药物输送系统
背景情况:
- 由于可变的生物可用性和胃肠道副作用,频繁的 Glipizide 剂量存在挑战.
- 传统的剂量形式可能无法优化glipizide的治疗结果.
研究的目的:
- 开发和评估粘粘膜口膜,用于持续的 Glipizide 输送.
- 在薄膜配方中使用与HPMC E15结合的天然蛋白质 (白蛋白,凝,素).
主要方法:
- 使用溶剂造技术制备了9种glipizide粘粘膜口膜配方 (F1-F9).
- 描述包括药物聚合物兼容性 (FT-IR,DSC),物理化学性质,体外透性研究和稳定性评估.
- 配方被评估为表面pH值,折叠耐力,水分含量,厚度,重量和胀指数.
主要成果:
- FT-IR和DSC证实没有显著的glipizide辅助剂不兼容性.
- 物理化学性质处于可接受范围内,稳定性测试3个月后的变化最小.
- 活体研究显示,在8个小时内持续释放glipizide (80.94%-90%),并观察到零级动力学. 配方F6是最佳的,达到89.29%的释放.
结论:
- 已开发的粘粘性口腔膜显示了glipizide的优异的持续释放特性.
- 这种创新的输送系统比传统的剂量形式提供了显著的改进.
- 这些电影有潜力通过改善生物可用性,患者遵守性和减少副作用来改善糖尿病管理.
相关概念视频
01:24Glucagon-like Receptor Agonists
438
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
438
01:19Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
278
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
278
01:23Dipeptidyl Peptidase 4 Inhibitors
271
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
271
01:20Factors Affecting Dissolution: Drug Permeability, Stability and Stereochemistry
269
Orally administered drugs primarily enter the systemic circulation via passive diffusion through the intestinal membranes. The drug's absorption is influenced by drug stability in the gastrointestinal GI tract, membrane permeability, the surface area available for absorption, luminal drug concentration, and residence time in the lumen. Drug permeability can be enhanced by adjusting the lipophilicity, polarity, or molecular size of the drug, promoting its passive transport across intestinal...
269
01:28Factors Influencing Drug Absorption: Pharmaceutical Parameters
198
Solid dosage forms such as tablets and capsules undergo rigorous manufacturing processes to ensure stability and effectiveness. Their dissolution and absorption properties are influenced significantly by the choice of excipients (inactive ingredients that serve various roles in the formulation), and the methodology applied during production. The manufacturing parameters, such as compression force and granulation techniques, significantly affect dissolution rates. Elevated compression forces...
198